Poster Round 1: Treatment of Helicobacter infection

P1.01                   

First-line H. pylori eradication therapy in Europe: Results from 21,487 cases of the European Registry on H. pylori Management (Hp-EuReg)

A. G. McNicholl1, O. P. Nyssen1, D. S. Bordin2, B. Tepes3, A. Perez-Aisa4, D. Vaira5, M. Caldas6, L. Bujanda7, M. Castro-Fernandez8, F. Lerang9, M. Leja10, L. Rodrigo11, T. Rokkas12, L. Kupcinskas13, J. Perez-Lasala14, L. V. Jonaitis15, O. Shvets16, A. Gasbarrini17, H. Simsek18, A. T. R. Axon19, G. M. Buzas20, J. C. Machado21, Y. Niv22, L. Boyanova23, A. Goldis24, V. Lamy25, M. Katicic26, K. Przytulski27, C. Beglinger28, M. Venerito29, P. Bytzer30, L. G. Capelle31, T. Milosavljevic32, L. I. Veijola33, J. Molina-Infante34, L. Vologhzanina35, G. Fadeenko36, I. Ariño37, G. Fiorini5, M. Ramas6, M. G. Donday6, F. Megraud38, C. O'Morain39, J. P. Gisbert1, On behalf of the Hp-EuReg Investigators; 1Hospital Universitario de la Princesa, IIS-IP, CIBER-EHD, and UAM, Madrid, Spain, 2Department of pancreatobiliary and upper GI diseases, Moscow Clinical Scientific Center, Moscow, Russian Federation, 3Gastroenterology Unit, AM DC Rogaska, Rogaska Slatina, Slovenia, 4Agencia Sanitaria Costa del Sol, Malaga, Spain, 5Gastroenterology Unit, S. Orsola Malpighi Hospital, Bologna, Italy, 6Hospital Universitario de la Princesa, Madrid, Spain, 7Department of Gastroenterology. Hospital Donostia/Instituto Biodonostia. Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd). Universidad del País Vasco (UPV/EHU),, Donosti, Spain, 8Digestive Unit, Hospital de Valme, Sevilla, Spain, 9Medical Department, Central Hospital Ostfold, Fredrikstad, Norway, 10Institute of Clinical and Preventive Medicine & Faculty of Medicine, University of Latvia, Riga, Latvia, 11Gastroenterology Unit, Hospital Universitario Central de Asturias, Oviedo, Spain, 12Gastroenterology Unit, Henry Dunant Hospital, Athens, Greece, 13Department of Gastroenterology, Lithuanian University of Health Sciences, Kaunas, Lithuania, 14Digestive Service, HM Sanchinarro, Madrid, Spain, 15Department of Gastroenterology, Lithuanian University of Health Sciences, Madrid, Spain, 16Internal Diseases Department No.1, National Medical University named after O.O. Bogomolets, Kyiv, Ukraine, 17Gastronterology Area, Fondazione Policlinico Universitario A. Gemelli, Rome, Italy, 18Internal Medicine/Gastroenterology department, Hacettepe University Faculty of Medicine, Ankara, Turkey, 19Gastroenterology Unit, University of Leeds, Leeds, United Kingdom, 20Gastroenterology Unit, Ferencváros Policlinic, Budapest, Hungary, 21Instituto de Investigação e Inovação em Saúde, Universidade do Porto, and Ipatimup - Institute of Molecular Pathology and Immunology of the University of Porto, Porto, Portugal, 22Department of Gastroenterology, Rabin Medical Center, Tel Aviv University, Tel Aviv, Israel, 23Department of Medical Microbiology, Medical University of Sofia, Sofia, Bulgaria, 24Gastroenterology Unit, Timisoara Hospital, Timisoara, Romania, 25Dpt. of Gastroenterology, Hepatology & Nutrition, CHU Charleroi, Charleroi, Belgium, 26Gastroenterology Unit, University Hospital Merkur Polyclinic Nola, Zagreb, Croatia, 27Gastroenterology Unit, Medical Centre for Postgraduate Education, Warsaw, Poland, 28Gastroenterology Unit, Hospital de Basel, Basel, Switzerland, 29Department of Gastroenterology, Hepatology and Infectious Diseases, Otto-von-Guericke University Hospital, Magdeburg, Germany, 30Department of Medicine, Zealand University Hospital, Copenhagen University, Copenhagen, Denmark, 31Gastroenterology and Hepatology, Erasmus MC University, Rotterdam, Netherlands, 32Medical Department, Clinical Center of Serbia Clinic for Gastroenterology and hepatology, University of Belgrade, Belgrade, Serbia, 33Internal Medicine, Herttoniemi Hospital, Helsinki, Finland, 34Gastroenterology Unit, Hospital San Pedro de Alcántara, Caceres, Spain, 35Gastroenterology Unit Gastrocentr, Perm, Perm, Russian Federation, 36Digestive Ukrainian Academy of Medical Sciences, Kyiv, Ukraine, 37Gastroenterology Unit, Hospital ClÍnico Universitario Lozano Blesa, Zaragoza, Spain, 38Laboratoire de Bactériologie, Hôpital Pellegrin, Bordeaux Cedex, France, 39Trinity College Dublin - Faculty of Health Sciences, Trinity College Dublin; Dublin/IE, Faculty of Health Sciences,, Dublin, Ireland.

P1.02                   

Efficacy of first-line regimens in Spain: results from the European Registry on H. pylori management (Hp-EuReg)

M. Caldas1, A. Pérez-Aisa2, M. Castro3, L. Bujanda4, A. J. Lucendo5, N. Fernández2, J. Hinojosa2, L. Rodrigo6, T. Romero-García3, L. Ferrer-Barceló7, H. Alonso-Galán4, J. Pérez-Lasala8, J. Molina-Infante9, L. Fernández-Salazar10, J. Barrio11, Á. Lanas12, M. Domínguez-Cajal13, M. Perona14, J. Ortuño15, B. J. Gómez-Rodriguez16, P. Canelles7, P. Almela17, P. L. González9, I. Modolell18, J. M. Botargués19, J. Gómez20, O. P. Nyssen1, A. C. Marín1, M. G. Donday1, A. Garre1, F. Megraud21, C. O´Morain22, A. G. McNicholl1, J. P. Gisbert1; 1Hospital de La Princesa, IIS-IP and CIBERehd, Madrid, Spain, 2Agencia Sanitaria Costa del Sol, Málaga, Spain, 3Hospital de Valme, Sevilla, Spain, 4Hospital Donostia/Instituto Biodonostia and CIBERehd. Universidad del País Vasco (UPV/EHU), San Sebastián, Spain, 5Hospital General de Tomelloso, Ciudad Real, Spain, 6Hospital Central de Asturias, Oviedo, Spain, 7Consorci Hospital General Universitari de Valencia, Valencia, Spain, 8HM Sanchinarro, Madrid, Spain, 9Hospital San Pedro de Alcántara, Cáceres, Spain, 10Hospital Clínico Universitario de Valladolid, Valladolid, Spain, 11Hospital Universitario Río Hortega, Valladolid, Spain, 12Hospital Clínico Universitario Lozano Blesa and CIBERehd, Zaragoza, Spain, 13Hospital General San Jorge, Huesca, Spain, 14Hospital Quirón Marbella, Málaga, Spain, 15Hospital Universitari y Politècnic La Fe de Valencia and CIBERehd, Valencia, Spain, 16Hospital Universitario Virgen Macarena, Sevilla, Spain, 17Hospital Universitari General de Castelló, Castellón, Spain, 18Consorci Sanitari de Terrassa, Barcelona, Spain, 19Hospital Universitari de Bellvitge, Barcelona, Spain, 20Complejo Asistencial Universitario de Burgos, Burgos, Spain, 21Laboratoire de Bactériologie, Hôpital Pellegrin, Bordeaux, France, 22Trinity College Dublin, Dublin, Ireland.

P1.03                   

Pan-European Registry on H. pylori Management (Hp-EuReg): Experience with single capsule bismuth quadruple therapy in 2,326 patients

A. G. McNicholl1, O. P. Nyssen1, A. Perez-Aisa2, D. Vaira3, B. Tepes4, M. Caldas5, L. Bujanda6, M. Castro-Fernandez7, L. Rodrigo8, J. Perez-Lasala9, A. Gasbarrini10, J. C. Machado11, M. Venerito12, G. Fiorini3, M. Ramas5, M. G. Donday5, F. Megraud13, C. O'Morain14, J. P. Gisbert1, On behalf of the Hp-EuReg Investigators; 1Hospital Universitario de la Princesa, IIS-IP, CIBER-EHD, and UAM, Madrid, Spain, 2Agencia Sanitaria Costa del Sol, Malaga, Spain, 3Gastroenterology Unit, S. Orsola Malpighi Hospital, Bologna, Italy, 4Gastroenterology Unit, AM DC Rogaska, Rogaska Slatina, Slovenia, 5Hospital Universitario de la Princesa, Madrid, Spain, 6Department of Gastroenterology. Hospital Donostia/Instituto Biodonostia. Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd). Universidad del País Vasco (UPV/EHU), Donosti, Spain, 7Digestive Unit, Hospital de Valme, Sevilla, Spain, 8Gastroenterology Unit, Hospital Universitario Central de Asturias, Oviedo, Spain, 9Digestive Service, HM Sanchinarro, Madrid, Spain, 10Gastronterology Area, Fondazione Policlinico Universitario A. Gemelli, Rome, Rome, Italy, 11Instituto de Investigação e Inovação em Saúde, Universidade do Porto, and Ipatimup - Institute of Molecular Pathology and Immunology of the University of Porto, Porto, Portugal, 12Department of Gastroenterology, Hepatology and Infectious Diseases, Otto-von-Guericke University Hospital, Magdeburg, Germany, 13Laboratoire de Bactériologie, Hôpital Pellegrin, Bordeaux Cedex, France, 14Trinity College Dublin - Faculty of Health Sciences, Trinity College Dublin; Dublin/IE, Faculty of Health Sciences,, Dublin, Ireland.

P1.04                   

Pan-European Registry on H. pylori Management (Hp-EuReg): first-line treatment use and efficacy trends in 2013-2018

A. G. McNicholl1, O. P. Nyssen2, D. S. Bordin3, B. Tepes4, A. Perez-Aisa5, D. Vaira6, M. Caldas2, L. Bujanda7, F. Lerang8, M. Leja9, T. Rokkas10, L. Kupcinskas11, L. V. Jonaitis11, O. Shvets12, A. Gasbarrini13, G. M. Buzas14, J. C. Machado15, Y. Niv16, L. Boyanova17, V. Lamy18, M. Venerito19, M. Katicic20, L. G. Capelle21, T. Milosavljevic22, G. Fiorini6, M. Ramas2, M. G. Donday2, F. Megraud23, C. O'Morain24, J. P. Gisbert1; 1Hospital Universitario de la Princesa, IIS-IP, CIBER-EHD, and UAM, Madrid, Spain, 2Hospital Universitario de la Princesa, Madrid, Spain, 3Department of pancreatobiliary and upper GI diseases, Moscow Clinical Scientific Center, Moscow, Russian Federation, 4Gastroenterology Unit, AM DC Rogaska, Rogaska Slatina, Slovenia, 5Agencia Sanitaria Costa del Sol, Malaga, Spain, 6Gastroenterology Unit, S. Orsola Malpighi Hospital, Bologna, Italy, 7Department of Gastroenterology. Hospital Donostia/Instituto Biodonostia. Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd). Universidad del País Vasco (UPV/EHU), Donosti, Spain, 8Medical Department, Central Hospital Ostfold, Fredrikstad, Norway, 9Institute of Clinical and Preventive Medicine & Faculty of Medicine, University of Latvia, Riga, Latvia, 10Gastroenterology Unit, Henry Dunant Hospital, Athens, Greece, 11Department of Gastroenterology, Lithuanian University of Health Sciences, Kaunas, Lithuania, 12Internal Diseases Department No.1, National Medical University named after O.O. Bogomolets, Kyiv, Ukraine, 13Gastronterology Area, Fondazione Policlinico Universitario A. Gemelli, Rome, Rome, Italy, 14Gastroenterology Unit, Ferencváros Policlinic, Budapest, Hungary, 15Instituto de Investigação e Inovação em Saúde, Universidade do Porto, and Ipatimup - Institute of Molecular Pathology and Immunology of the University of Porto, Porto, Portugal, 16Department of Gastroenterology, Rabin Medical Center, Tel Aviv University, Tel Aviv, Israel, 17Department of Medical Microbiology, Medical University of Sofia, Sophia, Bulgaria, 18Dpt. of Gastroenterology, Hepatology & Nutrition, CHU Charleroi, Charleroi, Belgium, 19Department of Gastroenterology, Hepatology and Infectious Diseases, Otto-von-Guericke University Hospital, Magdeburg, Germany, 20Gastroenterology Unit, University Hospital Merkur Polyclinic Nola, Zagreb, Croatia, 21Gastroenterology and Hepatology, Erasmus MC University, Rotterdam, Netherlands, 22Medical Department, Clinical Center of Serbia Clinic for Gastroenterology and hepatology, University of Belgrade, Belgrade, Serbia, 23Laboratoire de Bactériologie, Hôpital Pellegrin, Bordeaux Cedex, France, 24Trinity College Dublin - Faculty of Health Sciences, Trinity College Dublin; Dublin/IE, Faculty of Health Sciences,, Dublin, Ireland.

P1.05                   

Efficacy of second-line regimens in Spain: results from the European Registry on H. pylori management (Hp-EuReg)

M. Caldas1, A. Pérez-Aisa2, M. Castro3, L. Bujanda4, A. J. Lucendo5, N. Fernández2, J. Hinojosa2, L. Rodrigo6, M. Pabón-Carrasco3, L. Ferrer-Barceló7, H. Alonso-Galán4, J. Pérez-Lasala8, J. Molina-Infante9, B. Velayos10, J. Barrio11, Á. Lanas12, M. Domínguez-Cajal13, M. Perona14, T. Di Maira15, B. J. Gómez-Rodriguez16, E. Medina7, M. Roldán17, P. Mata-Romero9, I. Modolell18, J. Botargués19, M. Jiménez-Moreno20, O. P. Nyssen1, A. C. Marín1, M. G. Donday1, A. Garre1, F. Megraud21, C. O´Morain22, A. McNicholl1, J. P. Gisbert1; 1Hospital de La Princesa, IIS-IP and CIBERehd, Madrid, Spain, 2Agencia Sanitaria Costa del Sol, Málaga, Spain, 3Hospital de Valme, Sevilla, Spain, 4Hospital Donostia/Instituto Biodonostia and CIBERehd. Universidad del País Vasco (UPV/EHU), San Sebastián, Spain, 5Hospital General de Tomelloso, Ciudad Real, Spain, 6Hospital Central de Asturias, Oviedo, Spain, 7Consorci Hospital General Universitari de Valencia, Valencia, Spain, 8HM Sanchinarro, Madrid, Spain, 9Hospital San Pedro de Alcántara, Cáceres, Spain, 10Hospital Clínico Universitario de Valladolid, Valladolid, Spain, 11Hospital Universitario Río Hortega, Valladolid, Spain, 12Hospital Clínico Universitario Lozano Blesa and CIBERehd, Zaragoza, Spain, 13Hospital General San Jorge, Huesca, Spain, 14Hospital Quirón Marbella, Málaga, Spain, 15Hospital Universitari y Politècnic La Fe de Valencia and CIBERehd, Valencia, Spain, 16Hospital Universitario Virgen Macarena, Sevilla, Spain, 17Hospital Universitari General de Castelló, Castellón, Spain, 18Consorci Sanitari de Terrassa, Barcelona, Spain, 19Hospital Universitari de Bellvitge, Barcelona, Spain, 20Complejo Asistencial Universitario de Burgos, Burgos, Spain, 21Laboratoire de Bactériologie, Hôpital Pellegrin, Bordeaux, France, 22Trinity College Dublin, Dublin, Ireland.

P1.06                   

Optimum second-line regimens for Helicobacter pylori eradication: Interim results of an ongoing Cochrane systematic review

O. P. Nyssen1, A. C. Marin1, A. G. McNicholl1, V. Savarino2, X. Calvet3, G. I Leontiadis4, L. Fischbach5, Y. Yuan4, A. Crespo Cañizares6, G. Escobar Aguilar7, E. Fernández Martínez8, E. García García7, S. Hernandez Iglesias8, C. Martín-Saborido7, C. Sánchez Martín9, D. Varillas Delgado8, J. Lopez-Alcalde10, J. P. Gisbert1; 1H. La Princesa, IIS-IP and CIBERehd, Madrid, Spain, 2Dipartimento di Medicina Interna e Specialita Mediche, Universita di Genova, Genova, Italy, 3Servei de Malalties Digestives, Hospital de Sabadell & Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd) Departament de Medicina Universitat Autònoma de Barcelona, Sabadell, Spain, 4Department of Medicine, Division of Gastroenterology, McMaster University, Hamilton, ON, Canada, 5Department of Epidemiology, University of Arkansas for Medical Sciences, Little Rock, AR, United States, 6Facultad de Ciencias de la Salud, Universidad Francisco de Vitoria, Madrid, Spain, 7Fundación San Juan de Dios, Centro Universitario de CC de la Salud San Rafael and Universidad Antonio de Nebrija, Madrid, Spain, 8Universidad Francisco de Vitoria, Madrid, Spain, 9Departamento de Anestesiologia, Hospital Clínico San Carlos, Madrid, Spain, 10Cochrane Associate Center of Madrid, Clinical Biostatistics Unit, Hospital Universitario Ramón y Cajal (IRYCIS) and Universidad Francisco de Vitoria, Madrid, Spain.

P1.07                   

Effects of Helicobacter pylori eradication for recurrent neoplasia prevention after endoscopic submucosal dissection of gastric adenoma

S. Kim, H. Park, Y. Cho, H. Kim, M. Kang, H. Kim, H. Kim; Division of Gastroenterology, Department of Internal Medicine, Yonsei University Wonju College of Medicine, Wonju, South Korea, Wonju, Korea, Republic of.

P1.08                   

Clarithromycin resistance test could improve the eradication rate of H. pylori

J. Jung, J. Kwon, E. Kim; Daegu Catholic University School of Medicine, Daegu, Korea, Republic of.

P1.10                   

Single-capsule bismuth-quadruple therapy: 3 or 4 times daily? Spanish Data from the European Registry on H. pylori Management (Hp-EuReg)

O. P. Nyssen1, A. G. McNicholl1, B. Gomez-Rodriguez2, J. Barrio3, M. Castro-Fernandez4, M. Mego5, A. Perez-Aisa6, N. Fernandez-Moreno6, B. Gomez7, L. Titó7, E. Iyo8, P. Canelles9, E. Medina-Chulia9, A. J. Lucendo10, T. Di Maira11, F. Martinez-Cerezo12, Ó. Nuñez13, M. Barenys14, M. Perona15, A. Campillo16, P. Mata-Romero17, J. Santos-Fernandez18, A. Cerezo-Ruiz19, S. Lario20, M. Ramirez-Lázaro21, C. O'Morain22, F. Megraud23, J. P. Gisbert1, X. Calvet21; 1Hospital de La Princesa, IIS-IP, CIBERehd, Madrid, Spain, 2Hospital Virgen de la Macarena, Sevilla, Spain, 3Hospital Rio Ortega, Valladolid, Spain, 4Hospital de Valme, Sevilla, Spain, 5Hospital universitario general de Cataluña, Quirón Salud., San Cugat del Valles, Spain, 6Agencia Sanitaria Costa del Sol, Marbella, Málaga, Spain, 7Hospital de Mataro, Mataró, Barcelona, Spain, 8Hospital Comarcal de Inca, Mallorca, Spain, 9Consorci Hospital General Universitari, Valencia, Spain, 10Hospital Gennreal de Tomelloso, Ciudad Real, Spain, 11Hospital La Fe, Valencia, Spain, 12Hospital Sant Joan, Reus, Spain, 13Hospital Universitario Sanitas La Moraleja, Madrid, Spain, 14Hosptal de Viladecans, Barcelona, Spain, 15Hospital Quirón, Marbella, Málaga, Spain, 16Hospital Reina Sofía, Tudela, Spain, 17Hospital San Pedro de Alcantara, Cáceres, Spain, 18Hospital Clínico Universitario, Valladolid, Spain, 19Hospital Sierra de Segura, Jaén, Spain, 20Unitat de Malalties Digestives. Hospital de Sabadell. Institut Universitari Parc Taulí. UAB. CIberEHD, Sabadell, Spain, 21Unitat de Malalties Digestives. Hospital de Sabadell. Institut Universitari Parc Taulí. UAB. CIberEHD, SABADELL, Spain, 22Trinity College, Dublin, Ireland, 23National Reference Centre for Helicobacters, Bacteriology Laboratory, Pellegrin Hospital, Bordeaux, France.

P1.11                   

Ultimate eradication rate of Helicobacter pylori in Korea: A single center experience

M. Lee, G. Kim, B. Lee, E. Park, G. Song; Pusan National University Hospital, Busan, Korea, Republic of.

P1.12                   

The efficacy of Modified bismuth quadruple therapy for Helicobacter pylori infection in Korea. A single arm prospective observational study

J. Choe, S. Jung, S. Kim, J. Hyun, Y. Jung, J. Koo, H. Yim, S. Lee; Ansan Hospital, Korea University College of Medicine, Ansan si, Korea, Republic of.

P1.13                   

Effectiveness and safety of furazolidone-containing quadruple regimens in patients with Helicobacter pylori infection: a real-world practice patterns in a developing country

C. Song, Y. Xie, Y. Zhu, X. Shu, N. Lu; First Affiliated Hospital of Nanchang University, Nanchang, China.

P1.14                   

Comparative effect of Proton-pump Inhibitors on the Success of Quadruple Therapy for Helicobacter pylori Infection

D. Boltin1, Z. Levi1, R. Gingold-Belfer1, H. Schmilovitz-Weiss1, T. Shochat1, R. Dickman1, Y. Niv1, S. Birkenfeld2, I. Dotan1; 1Rabin Medical Center, Petah Tikva, Israel, 2Clalit Health Services, Tel Aviv, Israel.

P1.15                   

Antimicrobial susceptibility of Helicobacter suis, a zoonotic agent mainly associated with pigs and non-human primates

C. De Witte1, H. Berlamont1, S. De Bruyckere1, R. Ducatelle1, A. Smet2, F. Haesebrouck1; 1Department of Pathology, Bacteriology and Avian Diseases, Faculty of Veterinary Medicine, Ghent University, Merelbeke, Belgium, 2Laboratory of Experimental Medicine and Pediatrics, Faculty of Medicine and Health Sciences, Antwerp University, Antwerpen, Belgium.

P1.16                   

Efficacy of flavodoxin inhibitors against Helicobacter pylori drug-resistant clinical strains and in Hp-infected mice

J. Sancho1, S. Salillas1, M. Alías2, V. Michel3, A. Mahía4, A. Lucía1, L. Rodrigues1, J. Bueno1, J. J. Galano-Frutos1, H. de Reuse3, A. Velazquez-Campoy1, J. A. Carrodeguas1, C. Sostres1, J. Castillo1, J. A. Aínsa1, M. D. Díaz de Villegas1, Á. Lanas1, E. Touati1; 1Aragon Health Institute, Zaragoza, Spain, 2Institute for biocomputation and physics of complex systems, Zaragoza, Spain, 3Institute Pasteur, Paris, France, 4Institute for Biocomputation and Physics of Complex System, Zaragoza, Spain.

P1.17                   

Comparison of the efficacy of vonoprazan-based first-line and second-line eradication therapy for Helicobacter pylori infection between 2015 and 2018.

S. Nakagawa1,2, T. Shimoyama1,3, W. Onodera2, D. Chinda1, C. Iino1, S. Fukuda1; 1Hirosaki University Graduate School of Medicine, Hirosaki, Japan, 2Mutsu General Hospital, Mutsu, Japan, 3Aomori General Health Examination Center, Aomori, Japan.

P1.18                   

In vitro activity of a new synthesized silver ultra-nanoclusters (SUNc) against Helicobacter pylori

F. Sisto1, R. Grande2, V. Puca2, M. Scaltrito1, A. Aceto2, M. Ronci2, L. Scotti2; 1University of Milan, Milan, Italy, 2University of Chieti-Pescara, Chieti, Italy.

P1.19                   

The comparison of side effects of standard triple therapy and high-dose amoxicillin / bismuth therapy in eradication of H. pylori

O. Sjomina1,2, A. Lielause1, A. Rūdule2, E. Martinsone2, D. Pūpola2,3, R. Vangravs2, A. Kiršners2, S. Paršutins2, H. Gorskis2, I. Poļaka2, A. Jeniceka1, E. Cine1, G. Šķenders2, D. Razuka-Ebela1, M. Leja1,2,4; 1Faculty of Medicine, University of Latvia, Riga, Latvia, 2Institute of Clinical and Preventive Medicine, University of Latvia, Riga, Latvia, 3Latvian Biomedical Research and Study centre, Riga, Latvia, 4Digestive Diseases Centre GASTRO, Riga, Latvia.

P1.20                   

Pan-European registry on Helicobacter pylori management: results from Budapest, Hungary

G. M. Buzás; Ferencváros Health Centre, Department of Gastroenterology, Budapest, Hungary.

P1.21                   

Effect of Helicobacter pylori eradication on non-alcoholic fatty liver disease

Y. Park, T. Kim, H. Lee, J. Lee, J. Kim; Samsung Medical Center, Seoul, Korea, Republic of.

P1.22                   

Testing and Treatment of Helicobacter pylori Infection Among Patients with Lynch Syndrome: The MD Anderson Cancer Center Experience

S. Thirumurthi1, P. Lum1, D. Y. Graham2; 1MD Anderson Cancer Center, Houston, TX, United States, 2Baylor College of Medicine, Houston, TX, United States.

P1.24                   

Alterations in cholesterols of H. pylori cell membrane upon exposure to PPIs

F. Siavoshi1, S. Kadkhodaei1, S. Nanvazadeh2; 1Department of Microbiology, School of Biology, College of Science, University of Tehran, Tehran, Iran, Islamic Republic of, 2Oilseeds research and Development Company (ORDC) Quality control Lab, Pars Ghou factory, Tehran, Iran, Islamic Republic of.

P1.25                   

Use of probiotics in the Helicobacter pylori eradication in Italy: data from the Italian Registry on Helicobacter pylori treatment.

R. Zagari1, A. Romiti1, G. Fiorini1, I. Saracino1, D. Ribaldone2, A. Panarese3, F. Lella4, F. Gigliotti5, A. Gasbarrini6, O. Paoluzi7, G. Del Vecchio Blanco7, M. Romano8, B. Annibale9, L. Broglia10, R. Catanzaro11, C. Marfinati Hervoso12, F. Luzza13, G. Nardone14, R. Conigliaro15, R. Cannizzaro16, M. Pavoni1, B. Vaira1, R. Pellicano2, M. Ferrara5, F. Bazzoli1; 1Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy, 2General and Specialistic Medical Department, Division of Gastroenterology , AOU Città della Salute e della Scienza, Turin, Italy, 3Department of Gastroenterology and Digestive Endoscopy, IRCCS "Saverio De Bellis", Castellana Grotte (Bari), Italy, 4Gastroenterology Unit, Policlinico San Pietro, Bergamo, Italy, 5Gastroenterology and Endoscopic Unit, San Giovanni Calibita-Fatebenefratelli Hospital, Rome, Italy, 6Gastroenterology Area, Fondazione Policlinico Universitario A Gemelli, Università Cattolica, Rome, Italy, 7Department of System Medicine, University of Tor Vergata, Rome, Italy, 8Department of Precision Medicine "F. Magrassi", University of Campania, Naples, Italy, 9Medical-Surgical Department of Clinical Sciences and Translational Medicine, University Sapienza, Rome, Italy, 10Unit of Gastroenterology, SS Trinità Hospital, Borgomanero (Novara), Italy, 11Gastroenterology and Hepatology Service, Internal Medicine Unit, University Hospital "G. Rodolico", Catania, Italy, 12Division of Gastroenterology,"A. Manzoni" Hospital, Lecco, Italy, 13Department of Health Sciences, University Magna Græcia, Catanzaro, Italy, 14Department of Clinical Medicine and Surgery, Hepato-Gastroenterology Unit, University of Naples "Federico II", Naples, Italy, 15Gastroenterology and Digestive Endoscopy Department, Sant'Agostino Estense Hospital, Baggiovara (Modena), Italy, 16Department of Gastroenterology, Istituto Nazionale Tumori IRCCS, Aviano (Pordenone), Italy.

P1.26                   

The Effect of Rabeprazole Dosing Timing on Helicobacter pylori Eradication Efficacy

D. Cheung, S. Suk, S. Kim, S. Park; The Catholic University of Korea College of Medicine, Seoul, Korea, Republic of.

P1.27                   

Comparison of the eradication rate of second-line treatment according to the type of first-line therapies in Helicobacter pylori.

D. Kim, S. Jung, J. Park, J. Choe, S. Kim, J. Hyun, J. Koo, H. Yim, S. Lee; Korea University, Ansan, Korea, Republic of.

P1.28                   

Sertraline - an anti-depressive compound with an activity against Helicobacter pylori

P. Krzyżek1, R. Franiczek1, B. Krzyżanowska1, P. Migdał2, G. Gościniak1; 1Department of Microbiology, Wroclaw Medical University, Wrocław, Poland, 2Department of Environment, Hygiene and Animal Welfare, Wroclaw University of Environmental and Life Sciences, Wrocław, Poland.

P1.29                   

Management of Helicobacter pylori infection by clinicians in a developing country: a questionnaire analysis with latitudinal and longitudinal comparison

C. Song1, Y. Xie1, Y. Zhu1, W. Liu2, G. Zhang3, S. He4, P. Zheng5, C. Lan6, Z. Zhang7, R. Hu8, Q. Du9, J. Xu10, Y. Chen11, Z. Zeng12, H. Cheng13, X. Wang14, X. Zuo15, H. Lu16, T. Guo17, Z. Chen18, N. Lu1, Chinese Society of Gastroenterology, Chinese StudyGroup on Helicobacter Pylori and Peptic Ulcer; 1First Affiliated Hospital of Nanchang University, Nanchang, China, 2Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China, 3First Affiliated Hospital of Nanjing Medical University, Nanjing, China, 4First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China, 5Fifth Affiliated Hospital of Zhengzhou University, Zhengzhou, China, 6Daping Hospital, The Third Military Medical University, Chongqing, China, 7Nanjing first hospital, Nanjing Medical University, Nanjing, China, 8West China Hospital of Sichuan University, Chengdu, China, 9Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China, 10First Affiliated Hospital of Anhui Medical University, Hefei, China, 11Nanfang Hospital, Southern Medical University, Guangzhou, China, 12First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China, 13Peking University First Hospital, Beijing, China, 14Qinghai University Affiliated Hospital, Xining, China, 15Qilu Hospital, Shandong University, Jinan, China, 16Renji Hospital, Shanghai Jiao Tong University School of Medicine, Nanchang, China, 17Peking Union Medical College Hospital, Beijing, China, 18Zhongnan Hospital Affiliated to Wuhan University, Wuhan, China.

P1.30                   

Second line bismuth-containing quadruple therapy for Helicobacter pylori eradication in Korea

M. Cho, H. Hwang, Y. Kim, C. Lim, J. Oh; The Catholic University of Korea, Seoul, Korea, Republic of.

P1.31                   

Effects of the combination of Saccharomyces boulardii with sequential therapy in the eradication of Helicobacter pylori: A prospective randomized controlled study

S. Jamal, H. Seddik, H. Boutallaka, K. Loubaris, Y. Touibi, R. Berraida, I. El Koti, A. Benkirane; Mohammed V Military Training Hospital of Rabat, Rabat, Morocco.

P1.32                   

Inhibition of Helicobacter pylori growth by different probiotics and autoprobiotics in vitro

E. Ermolenko1,2, A. Molostova2, A. Svarval3, A. Gusev1, A. Morosova1, K. Ermolenko4, A. Suvorov1; 1Institute of Experimental Medicine, Saint-Petersburg, Russian Federation, 2Saint-Petersburg State University, Saint-Petersburg, Russian Federation, 3Saint-Petersburg Pasteur Institute, Saint-Petersburg, Russian Federation, 4Pediatric Research and Clinical Center for Infectious Diseases, Saint-Petersburg, Russian Federation.

P1.33                   

The efficacy of Lactobacillus acidophilus and rhamnosus in the modification of gut microbiota and reduction of Helicobacter pylori bacterial load- a double-blind, placebo-controlled, randomized trial

J. Liou, M. Wu, M. Chen; National Taiwan University Hospital, Taipei, Taiwan.

P1.34                   

The Effect of PPI pre-administration on Helicobacter pylori Eradication Efficacy

Y. Park, D. Cheung, J. Kim, S. Park; The Catholic University of Korea College of Medicine, Seoul, Korea, Republic of.

P1.35                   

Randomized controlled study to see the effects of a triple therapy including vonoprazan or rabeprazole for the second-line treatment

M. Hojo, K. Matsumoto, K. Izumi, N. Yatagai, Y. Akazawa, T. Takeda, K. Ueda, H. Ueyama, Y. Shimada, H. Sasaki, K. Matsumoto, D. Asaoka, A. Nagahara; Juntendo University School of Medicine, Tokyo, Japan.

P1.36                   

Inhibitory effects of ß-caryophyllene on Helicobacter pylori infection: a randomized double-blind, placebo-controlled study

H. Shim, J. Cho, C. Shin, H. Yoon, Y. Park, N. Kim, D. Lee; Seoul National University Bundang Hospital, Seongnam, Korea, Republic of.

P1.37                   

Patient education materials to improve care of Helicobacter pylori infection: development of new tools in collaboration with patients and health professionals

V. Lindecker-Cournil1, S. Schramm1, L. Le Goaster1, J. D. De Korwin2, E. Bara1, M. H. Rodde-Dunet1; 1French National Authority for Health, Saint-Denis, France, 2Department of internal medicine, Nancy University Hospital and University of Lorraine, Nancy, France.

P1.38                   

Management of Helicobacter pylori infection in Russian сlinical practice

I. Bakulin1, D. Bordin2, N. Bakulina1, T. Ilchishina3; 1North-Western State Medical University n. a. I. I. Mechnikov, Saint-Petersburg, Russian Federation, 2Moscow Clinical Scientific Center n.a. A.S. Loginov, Moscow, Russian Federation, 3SM-clinic, Saint-Petersburg, Russian Federation.

P1.39                   

The effect of rebamipide therapy on eradication rates and side effects during triple therapy of Helicobacter pylori infection

J. Moon1, D. Lee1, Y. Shin1, S. Lee1, T. Park1, S. Ryu1, Y. Kim1, S. Seol2; 1Inje University Seoul Paik Hospital, Seoul, Korea, Republic of, 2Inje University Busan Paik Hospital, Busan, Korea, Republic of.

P1.40                   

Amoxicillin transfer across the gastric mucosa in the rat model of atrophic gastritis

A. Sablina1, V. Zolotarev2, S. Aleksanin1, G. Rodionov1, I. Samusenko1; 1The Nikiforov Russian Center of Emergency and Radiation Medicine, Saint-Petersburg, Russian Federation, 2Pavlov Institute of Physiology, Russian Academy of Sciences, Saint-Petersburg, Russian Federation.

P1.41                   

Gastric microbiota and probiotics opportunities in Helicobacter pylori eradication in children.

E. A. Kornienko1, N. I. Parolova1, S. V. Ivanov2, D. S. Polev3, P. A. Zykin3, Y. D. Kondratenko3; 1Saint Petersburg State Pediatric Medical University, St. Petersburg,, Russian Federation, 2First Pavlov State Medical University of St. Petersburg, St. Petersburg,, Russian Federation, 3Saint Petersburg State University, St. Petersburg,, Russian Federation.

P1.42                   

Anti- bacterial activity of H2-blockers and vitamins B1 and B6 against H. pylori

F. Siavoshi1, A. Arven1, S. Kadkhodaei2, R. Malekzadeh3, P. Saniee4; 1Department of Microbiology, School of Biology, College of Science, University of Tehran, Tehran, Iran, Islamic Republic of, 2Department of Microbiology, School of Biology, University of College of Sciences, University of Tehr, Tehran, Iran, Islamic Republic of, 3Digestive Oncology Research Center, Digestive Disease Research Institute, Tehran University of Medical Sciences, Tehran, Iran, Islamic Republic of, 4Department of Microbiology, Faculty of Life Sciences and Biotechnology, Shahid Beheshti University, Tehran, Iran, Islamic Republic of.

P1.43                   

Nonpharmacologic remedies improve eradication of Helicobacter pylori in patients with duodenal ulcer

M. N. Rustamov1, N. V. Baryshnikova2,3, Y. P. Uspenskiy2,4; 1Belarusian State Medical University, Minsk, Belarus, 2Pavlov First St-Petersburg State Medical University, St-Petersburg, Russian Federation, 3Institute of experimental medicine, St-Petersburg, Russian Federation, 4Saint-Petersburg state pediatric medical University, St-Petersburg, Russian Federation.

P1.44                   

Inhibitory effects of PPIs on Proteus mirabilis urease activity

F. Siavoshi, S. Kadkhodaei, A. Hatefi; Department of Microbiology, School of Biology, College of Science, University of Tehran, Tehran, Iran, Islamic Republic of.

P1.45                   

Results of the analysis of Helicobacter pylori eradication efficiency in the Vinnytsia region (Ukraine)

I. Paliy, V. Chernobrovyi, S. Zaika, N. Kondratiuk; National Pirogov Memorial Medical University, Vinnytsya, Ukraine.

P1.46                   

Comparison of anti- H. pylori activity of statins with metronidazole and clarithromycin

F. Siavoshi1, A. Atif1, S. Kadkhodaei1, A. Foroumadi2, P. Saniee3; 1Department of Microbiology, School of Biology, College of Science, University of Tehran, Tehran, Iran, Islamic Republic of, 2Department of Medicinal Chemistry, Faculty of Pharmacy and The Institute of pharmaceutical Sciences, Tehran University of Medical Sciences, Tehran, Iran, Islamic Republic of, 3Department of Microbiology, Faculty of Life Sciences and Biotechnology, Shahid Beheshti University, Tehran, Iran, Islamic Republic of.

P1.47                   

Helicobacter pylori eradication strategy according to sequencing-based 23S ribosomal RNA point mutation associated with clarithromycin resistance

W. Shin, H. Kim; Kangdong Sacred Heart Hospital, Seoul, Korea, Republic of.

P1.48                   

Can metformin inhibit H. pylori growth? (in vitro study)

N. V. Baryshnikova1,2, Y. P. Uspenskiy1,3, Z. K. Gulunov3, A. V. Svarval4, A. N. Suvorov2; 1Pavlov First St-Petersburg State Medical University, St-Petersburg, Russian Federation, 2Institute of experimental medicine, Saint-Petersburg, Russian Federation, 3St-Petersburg State Pediatric Medical University, St-Petersburg, Russian Federation, 4Saint-Petersburg Pasteur Institute, Saint-Petersburg, Russian Federation.

P1.49                   

Risk Factors of Rebleeding among Patients with Nonvariceal Upper Gastrointestinal Bleeding with Anticoagulant Therapy

M. Joo1, J. Park1, A. Yoo1, W. Kim1, K. Lim1, B. Lee1, H. Chun2, S. Lee3; 1Korea University College of Medicine Guro Hospital, Seoul, Korea, Republic of, 2Korea University College of Medicine Anam Hospital, Seoul, Korea, Republic of, 3Korea University College of Medicine Ansan Hospital, Seoul, Korea, Republic of.

P1.50                   

Bismuth-based vs. standard triple therapy for the eradication of Helicobacter pylori in Belgium: preliminary results.

S. A. François1, S. Kindt1, F. Mana2, S. Cadranel3, P. Bontems3, V. Lamy4, R. Ntounda5, V. Y. Miendje Deyi6, E. Macken7; 1UZ Brussel, Brussels, Belgium, 2Sint Jan Kliniek, Brussels, Belgium, 3Huderf - CHU Brugmann, Brussels, Belgium, 4CHU de Charleroi, Brussels, Belgium, 5CHU Saint Pierre, Brussels, Belgium, 6CHU Brugmann, Brussels, Belgium, 7UZ Antwerpen, Antwerpen, Belgium.

P1.51                   

Efficacy of Levofloxacin-Based Third-Line Therapy for the Eradication of Helicobacter pylori in Seoul

D. Lee; Seoul Paik hosipital, Seoul, Korea, Republic of.

P1.52                   

Efficacy of levofloxacin-based third-line therapy for the eradication of Helicobacter pylori in central Seoul, Korea

J. Moon1, D. Lee1, Y. Shin1, S. Lee1, T. Park1, S. Ryu1, Y. Kim1, S. Seol2; 1Inje University Seoul Paik Hospital, Seoul, Korea, Republic of, 2Inje University Busan Paik Hospital, Busan, Korea, Republic of.

​

Poster Round 1: Drug Resistance and clinical issues

P1.53                   

Whole Genome Sequencing analysis for characterization of genomic variations associated with antimicrobial resistance among Greek Helicobacter pylori isolates

G. Papadopoulou1,2, B. Martinez-Gonzalez1, T. Karamitros1, P. Kollia2, A. F. Mentis1, D. N. Sgouras1; 1Laboratory of Medical Microbiology, Hellenic Pasteur Institute,, Athens, Greece, 2Department of Genetics and Biotechnology, Faculty of Biology, School of Science, National and Kapodistrian University of Athens, Athens, Greece.

P1.54                   

Prevalence of multidrug resistance rate of Helicobacter pylori in Korea: Nationwide multicenter study

C. Kee Don1, J. Kim2; 1University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea, Republic of, 2Inje Universitiy, Busan Paik Hospital, Busan, Korea, Republic of.

P1.55                   

Multicenter survey of antimicrobial resistance in Helicobacter pylori isolates in Greece - Trends of resistance 1998-2018

B. Martinez-Gonzalez1, S. Georgopoulos2, S. Michopoulos3, Y. Karayiannis1, C. Liatsos4, F. Megraud5, D. N. Sgouras1, A. F. Mentis1; 1Laboratory of Medical Microbiology, Hellenic Pasteur Institute,, Athens, Greece, 2Gastroenterology Department, Athens Medical, Paleo Faliron Hospital, Athens, Greece, 3Gastroenterology Unit, "Alexandra" Hospital,, Athens, Greece, 4Gastroenterology Department, 401 Army General Hospital of Athens, Athens, Greece, 5Laboratory of Bacteriology, University of Bordeaux, Bordeaux, France.

P1.56                   

Expression of efflux pump gene hefA, hefD and hefG in clinical isolated Helicobacter pylori strains

Y. Wang1, Z. Li2, Y. An3, Y. Wang4, Q. Zhao1, R. Zhao1, Y. He1, S. Wu1, Y. Xie1; 1The First Affiliated Hospital of Nanchang University, nanchang city, China, 2Department of Medical College, Nanchang University, nanchang city, China, 3School of Pharmacy, Nanchang University, nanchang city, China, 4School of pharmacy, Nanchang University, nanchang city, China.

P1.57                   

Prevalence of primary and secondary antimicrobial resistance of Helicobacter pylori isolates in Korea

E. Gong1, H. Na2, J. Ahn2, J. Lee2, K. Choi2, K. Jung2, D. Kim2, H. Song2, G. Lee2, H. Jung2; 1Gangneung Asan Hospital, University of Ulsan College of Medicine, Gangneung, Korea, Republic of, 2Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea, Republic of.

P1.58                   

Prevalence of Helicobacter pylori clarithromycin resistance in Central Hungary

É. Kocsmár1, G. Buzás2, I. Kocsmár1, I. Hritz3, A. Szijártó3, G. Lotz1; 12nd Department of Pathology, Semmelweis University, Budapest, Hungary, 2Department of Gastroenterology, Ferencváros Health Centre, Budapest, Hungary, Budapest, Hungary, 31st Department of Surgery, Semmelweis University, Budapest, Hungary.

P1.59                   

Knockout RND efflux pump gene could prevent the occurrence of antibiotic resistance gene mutation

Y. Wang1, Y. An2, L. Yan3, Y. Wang3, Q. Zhao1, R. Zhao1, Y. He1, S. Wu1, Y. Song1, Y. Song1; 1The First Affiliated Hospital of Nanchang University, nanchang city, China, 2School of pharmacy, Nanchang University, nanchang city, China, 3School of Pharmacy, Nanchang University, nanchang city, China.

P1.60                   

Knockout RND efflux pump gene may reverse antibiotic resistance in Helicobacter pylori

Y. Wang1, L. Yan2, Y. An2, Y. Wang2, Q. Zhao1, R. Zhao1, S. Wu1, Y. He1, Y. Song1, Y. Xie1; 1The First Affiliated Hospital of Nanchang University, nanchang city, China, 2School of pharmacy, Nanchang University, nanchang city, China

P1.61                   

Detection of clarithromycin resistance in Helicobacter pylori with whole genome sequencing and a webtool

M. Yusibova1, H. Hasman2, T. Frandsen1, L. Andersen1; 1Department of Clinical Microbiology, København Ø, Denmark, 2Antimicrobial Resistance Reference Laboratory, Statens Serum Institute, København S, Denmark.

P1.62                   

MALDI-TOF-MS as tool to identify clarithromycin-resistant H. pylori isolates in Gipuzkoa, Spain

M. Milagrosa1, M. Gómez Ruiz de Arbulo1, M. Alonso1, J. Lizasoain2, M. Fernández-Reyes1; 1Microbiology Department, Hospital Universitario Donostia-Instituto Biodonostia, San Sebastián, Spain, San Sebastian-Donostia, Spain, 2Gastroenterology Department, University Donostia Hospital-Biodonostia Institute, San Sebastián, Spain, San Sebastian-Donostia, Spain.

P1.63                   

Primary and secondary Helicobacter pylori resistance among Serbian adult population

V. Milivojevic1, D. Kekic2,3, L. Ranin2,3, B. Medic4,3, M. Kovijanic5, S. Srećković6, I. Jovanovic1,3, M. Krstic1,3, T. Milosavljevic7; 1Clinical center of Serbia, Clinic for gastroenterology and hepatology, Belgrade, Serbia, 2Institute for microbiology and immunology, Medical faculty, University of Belgrade,, Belgrade, Serbia, 3Faculty of Medicine, Belgrade, Serbia, 4Institute for pharmacology, Medical faculty, University of Belgrade,, Belgrade, Serbia, 5General hospital Pancevo, Serbia,, Belgrade, Serbia, 6Clinical Center „Zvezdara“, Belgrade, Serbia,, Belgrade, Serbia, 7General hospital Euromedic, Belgrade, Serbia., Belgrade, Serbia.

P1.64                   

The primary resistance of H. pylori strains from South-Western Polish pediatric and adult patients in 2016-2018

P. Krzyżek1, G. Gościniak1, B. Iwańczak2, D. Pawełka3, F. Mégraud4; 1Department of Microbiology, Wrocław Medical University, Wrocław, Poland, 2Department and Clinic of Pediatrics, Gastroenterology and Nutrition, Wrocław Medical University, Wrocław, Poland, 3Department and Division of Surgical Didactics, Wrocław Medical University, Wrocław, Poland, 4Université de Bordeaux, Centre National de Référence des Campylobacters et Hélicobacters, Bordeaux, France.

P1.65                   

Antimicrobial stewardship and Helicobacter pylori: A new beginning

D. Y. Graham; VA Medical Center, Houston, TX, United States.

P1.66                   

The comparison of new and classical point mutations associated with clarithromycin resistance in Helicobacter pylori strains isolated from dyspeptic patients and their effects on phenotypic clarithromycin resistance

B. S. Kocazeybek1, T. Ziver Sarp2, D. Ozbey1, N. Gareayaghi3; 1Istanbul University-Cerrahpasa, Cerrahpasa Faculty of Medicine, Medical Microbiology Department, Istanbul, Turkey, 2Eastern Mediterranean University, Faculty of Health Sciences, Nutrition and Dietetic Department,, Famagusta,, Cyprus, 3Istanbul Sisli Hamidiye Etfal Training and Research Hospital, Blood Center,, Istanbul, Turkey.

P1.67                   

Point mutations in the development of antibiotic resistance in Helicobacter pylori

Y. Wang1, Z. Li2, Y. An3, Q. Zhao1, R. Zhao1, Y. He1, S. Wu1, Y. Xie1; 1The First Affiliated Hospital of Nanchang University, nanchang city, China, 2Department of Medical College, Nanchang University, nanchang city, China, 3School of pharmacy, Nanchang University, nanchang city, China.

P1.68                   

The prevalence of single and multidrug antibiotic resistance in Helicobacter pylori isolated from Iranian dyspeptic patients

B. Attaran1, B. Ghadiri1, S. Kalateh1, N. Eskini1, R. Azimi1, M. Esmaeili1, M. Tashakoripoor2, M. Eshagh Hosseini2, M. Mohammadi1; 1HPGC Group, Medical Biotechnology Department, Pasteur Institute of Iran, Tehran, Iran, Islamic Republic of, 2Gastroenterology Department, Amiralam Hospital, Tehran, Iran, Islamic Republic of.

P1.69                   

Current resistance rate of Helicobacter pylori with Standard Triple Therapy in Libyan Dyspeptic Patients : - Preliminary results

A. R. Fitouri1, A. Nami2, A. Albeshte3, A. Berfad4, S. Benmasoud4, F. Al- Turjman5; 1Central Tripoli Hospital, Tripoli, Libyan Arab Jamahiriya, 2Biology Dept. Faculty of Arts and Sciences, Al-Mergib University, Kasr Khiar, Libyan Arab Jamahiriya, 3Tripoli Children Hospital, University of Tripoli, Tripoli, Libyan Arab Jamahiriya, 4Tripoli Children Hospital- University of Tripoli, Tripoli, Libyan Arab Jamahiriya, 5Pathology Dept. Faculty of Medicine , University of Tripoli., Tripoli, Libyan Arab Jamahiriya.

P1.70                   

Response to triple standard therapy > eradication of infection with Helicobacter pylori in a center of north-eastern Romania

E. V. Popovici1,2; 1County Clinical Emergency Hospital of Bacau, Romania, Bacau, Romania, 2Grigore T Popa “ University of Medicine and Pharmacy", Iasi, Romania.